{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:10:00Z","timestamp":1785726600156,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F30CA174058-01"],"award-info":[{"award-number":["F30CA174058-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s11060-017-2460-6","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T11:32:11Z","timestamp":1495711931000},"page":"531-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review"],"prefix":"10.1007","volume":"133","author":[{"given":"Timothy L.","family":"Sita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina G.","family":"Petras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q. Eileen","family":"Wafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Berendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim J.","family":"Kruser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"2460_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87\u2013108. doi:\n                    10.3322\/caac.21262","journal-title":"CA Cancer J Clin"},{"key":"2460_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330. doi:\n                    10.3322\/caac.21332","journal-title":"CA Cancer J Clin"},{"key":"2460_CR3","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1002\/cncr.26392","volume":"118","author":"E Scosyrev","year":"2012","unstructured":"Scosyrev E, Messing EM, Mohile S et al (2012) Prostate cancer in the elderly. Cancer 118:3062\u20133070. doi:\n                    10.1002\/cncr.26392","journal-title":"Cancer"},{"key":"2460_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/path.1700660112","volume":"66","author":"LM Franks","year":"1953","unstructured":"Franks LM (1953) The spread of prostatic carcinoma to the bones. J Pathol 66:91\u201393. doi:\n                    10.1002\/path.1700660112","journal-title":"J Pathol"},{"key":"2460_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1017\/S0317167100002250","volume":"29","author":"CE Erasmus","year":"2014","unstructured":"Erasmus CE, Verhagen WIM, Wauters CAP, Lindert EJV (2014) Brain metastasis from prostate small cell carcinoma: not to be neglected. Can J Neurol Sci 29:375\u2013377. doi:\n                    10.1017\/S0317167100002250","journal-title":"Can J Neurol Sci"},{"key":"2460_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/pros.22742","volume":"74","author":"G Gandaglia","year":"2014","unstructured":"Gandaglia G, Abdollah F, Schiffmann J et al (2014) Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74:210\u2013216. doi:\n                    10.1002\/pros.22742","journal-title":"Prostate"},{"key":"2460_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cncr.11522","volume":"98","author":"IW Tremont-Lukats","year":"2003","unstructured":"Tremont-Lukats IW, Bobustuc G, Lagos GK et al (2003) Brain metastasis from prostate carcinoma\u2014the M. D. Anderson cancer center experience. Cancer 98:363\u2013368. doi:\n                    10.1002\/cncr.11522","journal-title":"Cancer"},{"key":"2460_CR8","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512","journal-title":"N Engl J Med"},{"key":"2460_CR9","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MHA et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513\u20131520. doi:\n                    10.1056\/NEJMoa041318","journal-title":"N Engl J Med"},{"key":"2460_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983\u2013992. doi:\n                    10.1016\/S1470-2045(12)70379-0","journal-title":"Lancet Oncol"},{"key":"2460_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422. doi:\n                    10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"key":"2460_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.12998\/wjcc.v2.i6.228","volume":"2","author":"S De Placido","year":"2014","unstructured":"De Placido S, Rescigno P, Federico P et al (2014) Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. World J Clin Cases 2:228\u2013231. doi:\n                    10.12998\/wjcc.v2.i6.228","journal-title":"World J Clin Cases"},{"key":"2460_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187\u20131197. doi:\n                    10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"key":"2460_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223. doi:\n                    10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"key":"2460_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3816\/CCC.2009.n.016","volume":"8","author":"JP Mongan","year":"2009","unstructured":"Mongan JP, Fadul CE, Cole BF et al (2009) Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 8:100\u2013105. doi:\n                    10.3816\/CCC.2009.n.016","journal-title":"Clin Colorectal Cancer"},{"key":"2460_CR16","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/cncr.11436","volume":"97","author":"JC Bendell","year":"2003","unstructured":"Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972\u20132977. doi:\n                    10.1002\/cncr.11436","journal-title":"Cancer"},{"key":"2460_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11060-011-0734-y","volume":"107","author":"O Caffo","year":"2011","unstructured":"Caffo O, Gernone A, Ortega C et al (2011) Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol 107:191\u2013196. doi:\n                    10.1007\/s11060-011-0734-y","journal-title":"J Neurooncol"},{"key":"2460_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11060-012-0994-1","volume":"111","author":"O Caffo","year":"2013","unstructured":"Caffo O, Veccia A, Fellin G et al (2013) Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. J Neurooncol 111:163\u2013167. doi:\n                    10.1007\/s11060-012-0994-1","journal-title":"J Neurooncol"},{"key":"2460_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1200\/JCO.2005.04.6185","volume":"24","author":"D Khuntia","year":"2006","unstructured":"Khuntia D (2006) Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24:1295\u20131304. doi:\n                    10.1200\/JCO.2005.04.6185","journal-title":"J Clin Oncol"},{"key":"2460_CR20","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2301::AID-CNCR18>3.0.CO;2-D","volume":"86","author":"IE McCutcheon","year":"1999","unstructured":"McCutcheon IE, Eng DY, Logothetis CJ (1999) Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer 86:2301\u20132311","journal-title":"Cancer"},{"key":"2460_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1089\/jpm.2009.0416","volume":"13","author":"A Lawton","year":"2010","unstructured":"Lawton A, Sudakoff G, Dezelan LC, Davis N (2010) Presentation, treatment, and outcomes of dural metastases in men with metastatic castrate-resistant prostate cancer: a case series. J Palliat Med 13:1125\u20131129. doi:\n                    10.1089\/jpm.2009.0416","journal-title":"J Palliat Med"},{"key":"2460_CR22","first-page":"4357","volume":"34","author":"T Bartscht","year":"2014","unstructured":"Bartscht T, Rades D (2014) Predicting survival after whole-brain irradiation for cerebral metastases from prostate cancer. Anticancer Res 34:4357\u20134360","journal-title":"Anticancer Res"},{"key":"2460_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.surneu.2007.05.035","volume":"69","author":"S-H Kim","year":"2008","unstructured":"Kim S-H, Chao ST, Toms SA et al (2008) Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma. Surg Neurol 69: 641\u2013646. doi:\n                    10.1016\/j.surneu.2007.05.035","journal-title":"Surg Neurol"},{"key":"2460_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11060-009-9966-5","volume":"96","author":"T Flannery","year":"2010","unstructured":"Flannery T, Kano H, Niranjan A et al (2010) Stereotactic radiosurgery as a therapeutic strategy for intracranial metastatic prostate carcinoma. J Neurooncol 96:369\u2013374. doi:\n                    10.1007\/s11060-009-9966-5","journal-title":"J Neurooncol"},{"key":"2460_CR25","first-page":"203","volume":"24","author":"M Salvati","year":"2005","unstructured":"Salvati M, Frati A, Russo N et al (2005) Brain metastasis from prostate cancer. Report of 13 cases and critical analysis of the literature. J Exp Clin Cancer Res 24:203\u2013207","journal-title":"J Exp Clin Cancer Res"},{"key":"2460_CR26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s11255-013-0462-7","volume":"45","author":"CE Gzell","year":"2013","unstructured":"Gzell CE, Kench JG, Stockler MR, Hruby G (2013) Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature. Int Urol Nephrol 45:735\u2013742. doi:\n                    10.1007\/s11255-013-0462-7","journal-title":"Int Urol Nephrol"},{"key":"2460_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/cncr.20553","volume":"101","author":"RS McDermott","year":"2004","unstructured":"McDermott RS, Anderson PR, Greenberg RE et al (2004) Cranial nerve deficits in patients with metastatic prostate carcinoma\u2014clinical features and treatment outcomes. Cancer 101:1639\u20131643. doi:\n                    10.1002\/cncr.20553","journal-title":"Cancer"},{"key":"2460_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.radonc.2003.10.007","volume":"70","author":"JM O\u2019Sullivan","year":"2004","unstructured":"O\u2019Sullivan JM, Norman AR, McNair H, Dearnaley DP (2004) Cranial nerve palsies in metastatic prostate cancer\u2013results of base of skull radiotherapy. Radiother Oncol 70:87\u201390. doi:\n                    10.1016\/j.radonc.2003.10.007","journal-title":"Radiother Oncol"},{"key":"2460_CR29","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s00259-010-1489-y","volume":"37","author":"AAM van der Veldt","year":"2010","unstructured":"van der Veldt AAM, Hendrikse NH, Smit EF et al (2010) Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging 37:1950\u20131958. doi:\n                    10.1007\/s00259-010-1489-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2460_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1023\/A:1006494032052","volume":"50","author":"M Sanson","year":"2000","unstructured":"Sanson M, Napolitano M, Yaya R et al (2000) Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 50:245\u2013249. doi:\n                    10.1023\/A:1006494032052","journal-title":"J Neurooncol"},{"key":"2460_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745\u2013751","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2460_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","volume":"15","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M, Serizawa T, Shuto T et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15:387\u2013395. doi:\n                    10.1016\/S1470-2045(14)70061-0","journal-title":"Lancet Oncol"},{"key":"2460_CR33","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3389\/fonc.2016.00049","volume":"6","author":"JV Cohen","year":"2016","unstructured":"Cohen JV, Kluger HM (2016) Systemic immunotherapy for the treatment of brain metastases. Front Oncol 6:2018. doi:\n                    10.1159\/000376605","journal-title":"Front Oncol"},{"key":"2460_CR34","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697\u20131708. doi:\n                    10.1056\/NEJMoa1506859","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"2460_CR35","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/JCO.2016.34.15_suppl.5010","volume":"34","author":"M Hussain","year":"2016","unstructured":"Hussain M, Daignault S, Twardowski P, Albany C (2016) Co-targeting androgen receptor (AR) and DNA repair: a randomized ETS gene fusion-stratified trial of abiraterone\u2009+\u2009proednisone (Abi) +\/\u2212 the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)\u2014a University of Chicago phase II consortium trial. J Clin Oncol 34(Suppl):5010","journal-title":"J Clin Oncol"},{"key":"2460_CR36","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","volume":"13","author":"CK Donawho","year":"2007","unstructured":"Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728\u20132737. doi:\n                    10.1158\/1078-0432.CCR-06-3039","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-017-2460-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:27:00Z","timestamp":1589700420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-017-2460-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2460"],"URL":"https:\/\/doi.org\/10.1007\/s11060-017-2460-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]},"assertion":[{"value":"24 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TLS, KGP, QEW, MAB declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"TJK has served as a consultant for Varian Medical Systems, Inc, and on an advisory board for Abbvie, Inc. Neither of these activities pertains to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}